Abstract 69P
Background
PPIs taken before ICI may worsen outcomes in pts with solid tumors due to their gut microbiome disruptive effects, although no clear dose-dependent effect has been established yet.
Methods
We assessed the dose-dependent effects of PPIs on clinical outcomes in pts with stage IV solid tumors treated with PD-1/PD-L1 inhibitors at 17 Italian institutions from June 2014 to May 2020. PPI potency was standardized using the omeprazole equivalency (OE) method by Kirchheiner et al. An optimal OE cut-off was determined via the Youden index, categorizing pts into no PPI, low-potency PPI (≤13.5 mg/day OE), and high-potency PPI (>13.5 mg/day OE).
Results
Of the 675 pts included, 179 (26.5%) were on PPIs at baseline: 11.4% on low-potency and 15.1% on high-potency. Pts on PPIs were generally older, had poorer performance status (PS), higher disease burden, more baseline corticosteroid use, advanced-line treatment, and typically had non-small cell lung cancer. High-potency PPIs were associated with significantly worse overall survival (OS) (HR 1.55; 95% CI: 1.17-2.05) and progression-free survival (HR 2.02; 95% CI: 1.59-2.55) compared to no PPIs. Low-potency PPIs were not significantly associated with adverse outcomes. Multivariable Cox regression confirmed that only high-potency PPIs were associated with an increased risk of death (HR 1.55; 95% CI: 1.17-2.05), even after adjusting for potential confounders such as age, gender, PS, histology, disease burden, treatment line and baseline corticosteroid use. Double-adjusted propensity score matching confirmed the association between high-potency PPIs and poorer OS (HR 1.41; 95% CI: 1.04-1.92).
Conclusions
High-potency PPIs at baseline are associated with worse outcomes in pts treated with ICIs for stage IV solid tumors. Although further investigation is needed, these results suggest that PPIs should be used at the lowest effective dose to minimize potential detrimental effect.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract